British medical research teams have advanced clinical trial platforms, diagnostic tracking, and imaging technologies across multiple university sites, according to recent institutional disclosures. The developments span motor neuron disease screening at the University of Sheffield, heavy menstrual bleeding trials led by the Universities of Aberdeen and Edinburgh, and kidney care studies from The University of Manchester.
Pre-Trial Platform Accelerates Motor Neuron Disease Drug Screening
A clinical trial platform co-led by the University of Sheffield aims to accelerate treatments for motor neuron disease (MND) by identifying ineffective candidate drugs faster than traditional methods, according to university findings. The EXPERTS-ALS study screens potential therapeutics in patients with amyotrophic lateral sclerosis (ALS), the most common form of MND.
Rather than committing participants to year-long trials, the platform measures whether candidate drugs lower blood levels of neurofilament light chain (NFL), a protein biomarker linked to nerve cell damage. Using Bayesian modelling, researchers detect biological signals within 18 to 24 weeks using small sample sizes.
In initial testing, researchers halted evaluation of two repurposed drugs, metformin and nifedipine, after data showed neither lowered NFL levels. According to Chris McDermott, chief investigator and professor of translational neurology at the University of Sheffield, ruling out non-viable treatments with roughly 30 participants per arm ensures clinical resources target more promising therapies.
Did you know? Neurofilament light chain (NFL) serves as a blood-based protein biomarker that directly indicates nerve cell damage, allowing researchers to evaluate drug efficacy in a fraction of traditional trial timelines.
Oral Treatment Trial Targets Heavy Menstrual Bleeding
Researchers from the Universities of Aberdeen and Edinburgh secured nearly £2 million from the National Institute for Health and Care Research (NIHR) to lead a clinical trial evaluating an oral treatment for heavy menstrual bleeding, according to university announcements. The three-and-a-half-year study tests whether a daily pill provides an alternative to existing medical options.
Heavy menstrual bleeding affects one in three women, often forcing surgical interventions like hysterectomies that permanently end fertility. The trial examines relugolix combination therapy (relugolix-CT), which combines relugolix to temporarily halt the menstrual cycle with hormone replacement therapy to eliminate menopausal side-effects.
The study recruits 270 participants to compare relugolix-CT against standard care over 12 months, monitoring quality of life and NHS resource use. Siladitya Bhattacharya, trial co-lead and professor of women’s health at the University of Aberdeen, noted that the treatment offers a reversible medical alternative for patients.
Post-Hospital Care Gaps Identified in Acute Kidney Injury
Thousands of patients in England miss follow-up care after hospital discharge for acute kidney injury, according to a study led by The University of Manchester. Funded by the NIHR, researchers evaluated healthcare records for over 209,000 patients across 1,400 GP surgeries.
The findings indicate that only 19% of hospital acute kidney injury episodes were formally documented in primary care records within 30 days of discharge. Coding rates dropped lower among patients under 60 and those recovering from major surgery. Tom Blakeman, lead author and professor of primary care at The University of Manchester, stated that better integration of kidney health services is required to improve post-discharge outcomes.
Global Study Examines Sex Disparities in Tuberculosis
Men are significantly more likely to contract tuberculosis than women due to higher cumulative lifetime exposure rather than biological susceptibility, according to a global study led by UCL. The international research team analyzed data from over 22,000 individuals across 11 prospective cohort studies in 14 countries.
The findings show that men are more likely to host a latent TB infection at baseline. However, after accounting for initial infection status, men progress from infection to active disease at rates comparable to women. Yohhei Hamada, clinical research fellow from the UCL Institute for Global Health, explained that reducing inequalities in TB exposure among men addresses the primary driver of the sex gap.
Dundee Antimalarial Compound Advances in Early Trials
An antimalarial compound discovered at the University of Dundee demonstrated a favorable safety profile and efficacy in Phase II clinical trials in Africa, according to project disclosures. Developed by the Drug Discovery Unit with backing from Medicines for Malaria Venture, the molecule cabamiquine was evaluated in combination with pyronaridine.
Ian Gilbert, head of the drug discovery unit at the University of Dundee, noted that cabamiquine can be delivered as a single-dose treatment. The PAMAfrica consortium, managed by Merck, plans to advance the treatment to larger clinical trials and pediatric groups.
Standardised Guide Maps Ultrasound Detectors for Medical Imaging
Scientists from the University of Birmingham and UCL published an analysis of ultrasound detectors used in photoacoustic tomography, an imaging technology that uses light and sound to map blood vessels and tumors, according to university reports. The research team evaluated performance across 82 ultrasound detectors to establish a noise-equivalent pressure landscape.
The study found that large ceramic piezoelectric detectors offer sensitivity for deep-tissue applications like breast cancer screening, while optical sensors excel in micro-resolution imaging of vascular structures. Lead author James Guggenheim, Royal Society university research fellow at the University of Birmingham, stated that the guide helps manufacturers select detector technologies for specific clinical challenges.
Frequently Asked Questions
What is the EXPERTS-ALS platform?
According to the University of Sheffield, EXPERTS-ALS is a pre-trial platform designed to screen potential therapeutics in people with ALS by measuring blood levels of neurofilament light chain to detect early biological signals of disease-slowing.
How does relugolix-CT treat heavy menstrual bleeding?
According to the Universities of Aberdeen and Edinburgh, relugolix-CT combines relugolix to temporarily halt the menstrual cycle with hormone replacement therapy to prevent menopausal side-effects as a reversible medical alternative to surgery.
Why do men contract tuberculosis at higher rates than women?
According to UCL, higher rates of tuberculosis in men are driven by greater social and environmental exposure to the bacteria rather than an innate biological susceptibility.
What advantages does the antimalarial compound cabamiquine offer?
According to the University of Dundee, cabamiquine provides a favorable safety profile and can be delivered in a single dose when combined with pyronaridine.
Stay Informed on Medical Research
Subscribe to our updates to receive the latest peer-reviewed findings, clinical trial updates, and healthcare policy developments directly in your inbox.
Worth a look